When hypotension co-occurs with malignant tumors, the mortality rate further increases.[37] Patients with hyperkalemia using angiotensin receptor–neprilysin inhibitors may also experience hypotension and vasogenic edema, thereby increasing mortality risk.[38] However, the mortality rate increases slightly when the minimal average blood pressure exceeds a certain threshold. Here, MME is linked to Hyperkalemia.